ondansetron has been researched along with topiramate in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (35.29) | 29.6817 |
| 2010's | 9 (52.94) | 24.3611 |
| 2020's | 2 (11.76) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Kaplan, AS | 1 |
| Kenna, GA; McGeary, JE; Swift, RM | 1 |
| Egli, M; Heilig, M | 1 |
| Johnson, BA | 2 |
| Berglund, M; Gorelick, D; Hesselbrock, V; Johnson, BA; Kranzler, HR; Möller, HJ; Soyka, M | 1 |
| Bond, C; Breslin, FJ; Johnson, BA; Lynch, WJ | 1 |
| Amore, M; Ciccocioppo, R; Donnini, C; Gerra, G; Gerra, ML; Kalluppi, M; Malagoli, M; Raggi, MA; Saracino, MA; Somaini, L | 1 |
| Bond, CW; Johnson, BA; Lycas, MD; Lynch, WJ; Moore, CF | 1 |
| Aletraris, L; Paino, M; Roman, PM | 1 |
| Alto, M; Giusto, A; Greene, MC; Johnson, RM; Kane, J; Lovero, K; McClendon, J; Nicholson, T; Stockton, M; Tol, WA; Wainberg, ML | 1 |
8 review(s) available for ondansetron and topiramate
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Pharmacotherapy, pharmacogenomics, and the future of alcohol dependence treatment, Part 2.
Topics: Alcohol Deterrents; Alcoholism; Aripiprazole; Behavior Therapy; Disulfiram; Fructose; Humans; Naltrexone; Ondansetron; Pharmacogenetics; Piperazines; Quinolones; Topiramate | 2004 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Disease Models, Animal; Disulfiram; Fructose; Humans; Naltrexone; Neuropeptide Y; Nociceptin; Ondansetron; Opioid Peptides; Receptor, Cannabinoid, CB1; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Taurine; Topiramate | 2006 |
Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings.
Topics: Acamprosate; Alcoholism; Animals; Baclofen; Disulfiram; Fructose; Humans; Naltrexone; Ondansetron; Receptors, N-Methyl-D-Aspartate; Ritanserin; Selective Serotonin Reuptake Inhibitors; Taurine; Topiramate | 2008 |
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Substance Use and Related Disorders, Part 1: Alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Biological Psychiatry; Carbamazepine; Disulfiram; Fructose; Health Planning Guidelines; Humans; Naltrexone; Ondansetron; Societies, Scientific; Substance-Related Disorders; Taurine; Topiramate | 2008 |
Medication treatment of different types of alcoholism.
Topics: Adult; Aged; Alcohol Deterrents; Alcoholism; Baclofen; Chronic Disease; Depressive Disorder; Female; Fructose; Humans; Hypothalamo-Hypophyseal System; Limbic System; Male; Naltrexone; Ondansetron; Pituitary-Adrenal System; Prefrontal Cortex; Receptors, Dopamine D2; Receptors, GABA; Topiramate; Young Adult | 2010 |
Promising medications for cocaine dependence treatment.
Topics: Acetylcysteine; Atomoxetine Hydrochloride; Baclofen; Benzhydryl Compounds; Buprenorphine; Cocaine-Related Disorders; Fructose; Humans; Modafinil; Ondansetron; Patents as Topic; Propylamines; Topiramate | 2011 |
Psychosocial and pharmacologic interventions to reduce harmful alcohol use in low- and middle-income countries.
Topics: Acamprosate; Alcoholism; Amitriptyline; Developing Countries; Disulfiram; Humans; Male; Mirtazapine; Naltrexone; Ondansetron; Topiramate | 2023 |
9 other study(ies) available for ondansetron and topiramate
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Academy for Eating Disorders International Conference on Eating Disorders. Denver, CO, USA, May 29-31, 2003.
Topics: Anti-Obesity Agents; Antidepressive Agents, Tricyclic; Bulimia; Fructose; Humans; Ondansetron; Serotonin Antagonists; Topiramate | 2003 |
Severity of drinking as a predictor of efficacy of the combination of ondansetron and topiramate in rat models of ethanol consumption and relapse.
Topics: Alcohol Drinking; Alcoholism; Animals; Behavior, Animal; Disease Models, Animal; Drug Therapy, Combination; Ethanol; Fructose; GABA Modulators; Male; Ondansetron; Rats; Rats, Wistar; Secondary Prevention; Serotonin 5-HT3 Receptor Antagonists; Severity of Illness Index; Time Factors; Topiramate; Treatment Outcome | 2011 |
Acute and chronic administration of a low-dose combination of topiramate and ondansetron reduces ethanol's reinforcing effects in male alcohol preferring (P) rats.
Topics: Alcohol-Related Disorders; Animals; Behavior, Animal; Disease Models, Animal; Drug Administration Schedule; Drug Therapy, Combination; Ethanol; Fructose; GABA Modulators; Male; Ondansetron; Rats; Reinforcement Schedule; Serotonin Antagonists; Time Factors; Topiramate | 2014 |
The use of off-label medications in substance abuse treatment programs.
Topics: Accreditation; Adrenergic alpha-2 Receptor Agonists; Anticonvulsants; Antiemetics; Baclofen; Clonidine; Excitatory Amino Acid Antagonists; GABA Agents; Gabapentin; Health Facility Size; Humans; Logistic Models; Off-Label Use; Ondansetron; Practice Patterns, Physicians'; Substance Abuse Treatment Centers; Substance-Related Disorders; Time Factors; Topiramate; United States; Valproic Acid | 2020 |